Tremendous advances have occurred over the past 30 years in the diagnosis and management of neonatal herpes simplex virus (HSV) disease. Mortality in patients with disseminated disease has decreased from 85 to 29%, and that in patients with central nervous system (CNS) disease has decreased from 50 to 4%. Morbidity has been improved more modestly: the proportion of patients with disseminated disease who are developing normally at 1 year has increased from 50 to 83%. While the proportion of patients with neurologic morbidity following CNS disease has remained essentially unchanged over the past three decades, the total number of patients who are developing normally following HSV CNS disease has increased due to the improved survival. Although additional therapeutic advances in the future are possible, more immediate methods for further improvements in outcome for patients with this potentially devastating disease lie in an enhanced awareness of neonatal HSV infection and disease. A thorough understanding of the biology and natural history of HSV in the gravid woman and the neonate provides the basis for such an index of suspicion and is provided in this article.

中文翻译：

---

新生儿单纯疱疹感染。

在过去的30年中，新生儿单纯疱疹病毒（HSV）疾病的诊断和管理取得了巨大的进步。传播疾病患者的死亡率从85％降低到29％，中枢神经系统（CNS）患者的死亡率从50％降低到4％。发病率已得到适度改善：在1年内正常发展的传播疾病患者比例从50％增加到83％。在过去的三十年中，CNS疾病后神经系统疾病患者的比例基本保持不变，但由于生存期的提高，HSV CNS疾病后正常发育的患者总数有所增加。尽管将来可能会有更多的治疗进展，对于患有这种潜在破坏性疾病的患者，进一步改善结果的更直接的方法在于增强对新生儿HSV感染和疾病的认识。对妊娠妇女和新生儿中HSV的生物学和自然史的透彻了解为此类怀疑指数提供了依据，并在本文中提供。